FOXQ1 and neoplasm: One study judged FOXQ1 not to be a useful prognostic marker in CRC when it was investigated for predicting outcome, thus, if elevated in the primary CRC tumor there was a 5-years survival in the high group of 52% compared to 66% in the low group (P=0.11) (7).